REBUILDING BRIDGES IN THE GUT-LIVER AXIS: MICROBIOME AND BARRIER INTEGRITY IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE THERAPY

Read full text Summarise with VIRAT
Authors: K. B. Kvit, V. V. Kharchenko, B. B. Bodrevych
Cited by: 0
References: 17

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is considered a multifactorial disorder that develops in the context of metabolic disturbances and systemic inflammation.Recent scientific data indicate an important role of the interaction between the gut and the liver in the development of this pathology.Changes in the composition of the intestinal microbiota and impairment of the intestinal barrier function may facilitate the entry of microbial components into the portal circulation, which potentially activates inflammatory mechanisms in the liver and sustains metabolic dysfunction.One of the markers of impaired intestinal barrier integrity is considered to be zonulin, a regulator of intercellular tight junctions of the intestinal epithelium.The aim of the study was to determine the association between indicators of intestinal permeability, characteristics of the intestinal microbiome, and clinical and metabolic features in patients with MASLD, as well as to evaluate possible changes in these parameters under the influence of therapy aimed at microbiome modification.The study involved 152 patients with MASLD and 47 individuals without signs of liver disease, who constituted the control group.Anthropometric, biochemical, and metabolic parameters were assessed.Analysis of the intestinal microbiome composition was performed using quantitative real-time PCR, and the concentration of fecal zonulin was determined by enzyme-linked immunosorbent assay.As part of the treatment, a comprehensive approach was applied, including lifestyle modification and microbiome-oriented therapy.Patients with MASLD demonstrated more pronounced metabolic disturbances, elevated levels of liver enzymes and inflammatory markers, as well as significantly higher levels of fecal zonulin compared with the control group.After treatment, improvement in metabolic parameters, a decrease in zonulin levels, and changes in the intestinal microbial profile were observed, indicating partial restoration of the intestinal barrier function.The results of the study demonstrate that MASLD is associated with intestinal microbiome dysbiosis and increased intestinal permeability, and that microbiome-targeted therapy may contribute to the restoration of intestinal barrier function and improvement of metabolic parameters.

Fields of Study & Subjects

Gut microbiota and health Liver Disease Diagnosis and Treatment Gastrointestinal motility and disorders

Publication details

Journal / source
Bulletin of Problems Biology and Medicine
Volume
1
Issue
1
Pages
259–259
Publication date
1 January 2026
Language
EN